Christopher P. Molineaux - 15 Jun 2023 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role: Director
Signature: /s/ Mark Ballantyne, Attorney-in-Fact
Issuer symbol: ACRS
Transactions as of: 15 Jun 2023
Net transactions value: +$338
Form type: 4
Filing time: 20 Jun 2023, 16:31:10 UTC
Previous filing: 05 Jun 2023
Next filing: 22 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRS	Common Stock	Options Exercise	$36.72	+51	+0.16%	$0.7200^*	31,805	15 Jun 2023	Direct
transaction	ACRS	Common Stock	Options Exercise	$301	+198	+0.62%	$1.52^*	32,003	15 Jun 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACRS	Stock Option (right to buy)	Options Exercise	$0	-51	-100%	$0.000000^*	0	15 Jun 2023	Common Stock	51	$0.7200	Direct	F1
transaction	ACRS	Stock Option (right to buy)	Options Exercise	$0	-198	-100%	$0.000000^*	0	15 Jun 2023	Common Stock	198	$1.52	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of the shares underlying this option vested on August 13, 2015 and the remaining shares vested in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer as of the applicable vesting date.
F2	25% of the shares underlying this option vested on December 8, 2015 and the remaining shares vested in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer as of the applicable vesting date.